Topic: Chutes and Ladders
Endo's Paul Campanelli is officially out as CEO. With his CFO's move to the helm and an M&A specialist joining the board, are deals on the way?
Muzammil Mansuri, Sanofi’s EVP of strategy and business development since February 2016, is retiring at the end of November.
David Meline, the chief financial officer Amgen tapped on the eve of its major restructuring in 2014, is set to retire at the end of 2019.
Victor Bulto, who was key in Cosentyx's launch in the U.S., will succeed Fabrice Chouraqui as president of Novartis Pharmaceuticals U.S.
GSK has seen plenty of changes across its executive ranks over the last couple of years as CEO Emma Walmsley took the helm, but they’re still coming.
Gilead CEO Daniel O’Day has some holes to fill when it comes to exec hiring. But he insists the C-suite search won’t slow the company’s M&A search.
After seven years running Vertex, CEO Jeffrey Leiden is stepping up to executive chairman—and handing off his current job to CMO Reshma Kewalramani.
Sir Philip Hampton has served as GlaxoSmithKline's chairman during a turbulent period, and now he's handing off the reins to Jonathan Symonds.
New Gilead CEO Daniel O’Day has already replaced some key leaders at the company, but he’s not stopping there with the executive overhaul.
Jonathan Symonds, with plenty of experience in major life science deals, could be a strong fit for GSK as it looks to separate consumer health with pharma.